This renders CD39 a candidate marker for activated, more differentiated, and antigen-specific CD4+ T-cells in SARS-CoV-2 infection, similar to the already known CD39 expression by tumor-reactive T-cells [81,82]. This evidence concerns the gene CD4 and neoplasm.